Palisade Bio Net Worth
Palisade Bio Net Worth Breakdown | PALI |
Palisade Bio Net Worth Analysis
Palisade Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Palisade Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Palisade Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Palisade Bio's net worth analysis. One common approach is to calculate Palisade Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Palisade Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Palisade Bio's net worth. This approach calculates the present value of Palisade Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Palisade Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Palisade Bio's net worth. This involves comparing Palisade Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Palisade Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Palisade Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Palisade Bio's net worth research are outlined below:
| Palisade Bio generated a negative expected return over the last 90 days | |
| Palisade Bio has high historical volatility and very poor performance | |
| Palisade Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 250 K. Net Loss for the year was (12.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Palisade Bio currently holds about 5 M in cash with (11.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23. | |
| Palisade Bio has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Palisade Bio Now Covered by Brookline Capital Management |
Palisade Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Palisade Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Palisade Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Palisade Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Palisade Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Palisade Bio backward and forwards among themselves. Palisade Bio's institutional investor refers to the entity that pools money to purchase Palisade Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 52 K | Ubs Group Ag | 2024-06-30 | 1.2 K | Tower Research Capital Llc | 2024-06-30 | 738 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 280 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 100.0 | Wells Fargo & Co | 2024-06-30 | 21.0 | Bank Of America Corp | 2024-06-30 | 5.0 | Fidelity Management And Research Company | 2024-06-30 | 0.0 |
Follow Palisade Bio's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.73 M.Market Cap |
|
Project Palisade Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.88) | (0.92) | |
| Return On Capital Employed | (1.14) | (1.20) | |
| Return On Assets | (0.88) | (0.92) | |
| Return On Equity | (1.09) | (1.14) |
When accessing Palisade Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Palisade Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Palisade Bio's profitability and make more informed investment decisions.
Evaluate Palisade Bio's management efficiency
Palisade Bio has return on total asset (ROA) of (0.5853) % which means that it has lost $0.5853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1009) %, meaning that it created substantial loss on money invested by shareholders. Palisade Bio's management efficiency ratios could be used to measure how well Palisade Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.92. The current Return On Capital Employed is estimated to decrease to -1.2. As of now, Palisade Bio's Fixed Asset Turnover is decreasing as compared to previous years. The Palisade Bio's current Asset Turnover is estimated to increase to 0.04, while Total Assets are projected to decrease to under 12.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 24.81 | 23.57 | |
| Tangible Book Value Per Share | 24.81 | 23.57 | |
| Enterprise Value Over EBITDA | 0.65 | 0.69 | |
| Price Book Value Ratio | 0.36 | 0.34 | |
| Enterprise Value Multiple | 0.65 | 0.69 | |
| Price Fair Value | 0.36 | 0.34 | |
| Enterprise Value | -9.2 M | -8.8 M |
The decision-making processes within Palisade Bio are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 234.8894 | Return On Equity (1.10) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Palisade Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Palisade Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Palisade Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Palisade Bio Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 21st of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Palisade Bio Earnings per Share Projection vs Actual
Palisade Bio Corporate Management
| Joerg Heyer | Head Medicine | Profile | |
| Ryker Willie | Senior Controller | Profile | |
| Sharon McBrayer | Director Operations | Profile | |
| Mitchell MD | Chief Officer | Profile | |
| Robert McRae | VP Devel | Profile | |
| MD FAAAAI | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.26) | Return On Assets (0.59) | Return On Equity (1.10) |
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.